CDSCO: Lists notice on government analysts at CCSNIAH

The Central Drugs Standard Control Organisation (CDSCO) has listed notification S.O. 5617(E), dated 13 October 2026, concerning government analysts for veterinary vaccines at the Chaudhary Charan Singh National Institute of Animal Health (CCSNIAH) in Baghpat, Uttar Pradesh. Its Gazette Notifications page records 13 October 2026 as the release date.

The entry follows an earlier CDSCO listing concerning the institute’s designation as a Central Drugs Laboratory for testing viral and bacterial veterinary vaccines. Together, the entries document separate notifications concerning the laboratory and its government analysts, rather than an announcement approving a particular vaccine.

The October listing identifies the subject and notification number but does not reproduce the appointment provisions. It does not name the analysts, specify their number or set out the territorial scope of their authority. The release date recorded on the webpage should therefore not be treated as establishing when individual appointments took effect.

Laboratory designation preceded the analyst notification

CDSCO’s Gazette Notifications page records a draft notification, G.S.R. 65(E), dated 28 January 2026, proposing to designate CCSNIAH as a Central Drugs Laboratory for testing viral and bacterial veterinary vaccines under the Drugs and Cosmetics Act. A draft records a proposed regulatory change, rather than establishing by itself that the proposal has taken effect.

The same page subsequently lists G.S.R. 496(E), dated 18 June 2026, concerning that designation without the draft label. The October entry concerns government analysts at the institute, a different subject from the laboratory designation recorded in June.

CCSNIAH’s own website describes the institute as a Central Drugs Laboratory approved by the Ministry of Health and Family Welfare for quality control of veterinary biologicals in India. Veterinary biologicals include the animal vaccines that are the subject of the CDSCO notifications. Quality-control testing examines products against specified standards; it is distinct from administering vaccines to animals.

The institute says it works under the Department of Animal Husbandry and Dairying in the Ministry of Fisheries, Animal Husbandry and Dairying. Its administrative ministry is therefore distinct from the Ministry of Health and Family Welfare, which it identifies as the authority approving its Central Drugs Laboratory role.

In its organisational information, CCSNIAH lists three objectives: acting as a nodal institute to recommend licensing of veterinary vaccines, providing quality-control facilities for veterinary vaccines and diagnostics, and making standards available for veterinary biologicals and diagnostics. Diagnostics are products used to identify disease or other biological conditions. Recommending licensing, as described by the institute, is not the same as issuing a licence.

CCSNIAH also identifies harmonisation of vaccine and diagnostic quality with global standards as an institutional objective. In practical terms, harmonisation means aligning the standards against which products are assessed. The institute says common standards can bring vaccine manufacturers and quality-control testing institutions onto a shared platform.

These are the institute’s stated aims, not measured outcomes attributed to the October notification. Its organisational information also commits to continual improvement in testing, timely service, technological upgrades and compliance with applicable requirements. Those commitments describe how CCSNIAH intends to serve its users; they do not establish that the analyst notification changes testing capacity or turnaround times.

Why the appointment’s exact scope matters

A government analyst is an officially appointed analyst whose authority is defined by the relevant notification. An earlier Ministry of Health and Family Welfare notification illustrates why the product categories and geographical scope of an appointment matter.

In S.O. 567(E), dated 6 February 2024, the ministry appointed two research assistants at the Central Drugs Testing Laboratory, Indore, as government analysts under Section 20(2) of the Drugs and Cosmetics Act, 1940. That provision was the statutory authority cited for those appointments: the notification used it to identify the people authorised and the drug categories covered.

The appointees were Arijit Saha, Research Assistant in Biochemistry, and Turjya Ray, Research Assistant in Pharmaceutical Chemistry, according to the ministry’s notification. Although the notification was dated 6 February, the Gazette issue carrying it was dated 7 February 2024, distinguishing the document’s date from its publication date.

The Indore notification expressly made the appointments applicable across India, but excluded specified classes of drugs. Vaccines for veterinary use were among the exclusions, alongside veterinary anti-sera, toxoids and diagnostic antigens. These are different categories of biological products, rather than a single interchangeable class covered by every analyst appointment.

The document therefore shows that an appointment as a government analyst does not necessarily cover every category of product tested within the wider regulatory system. Both the territorial wording and the listed exceptions determine the boundaries of that particular authorisation.

That notification concerns Indore, not Baghpat. Its statutory basis, territorial coverage and exclusions cannot be assumed to apply to the CCSNIAH appointments merely because both notifications concern government analysts.

For Baghpat, the supported development is narrower: CDSCO has listed an October notification specifically concerning government analysts for veterinary vaccines, following the June laboratory-designation entry. The institute separately describes its work as quality-control testing and the provision of standards and testing facilities.

The full text of the October notification was not available for this report. The names of the appointed analysts, the precise vaccine categories covered, any conditions on their authority and the commencement terms remain to be established from S.O. 5617(E), rather than inferred from its listing title.